Magnapen treatment of infections in the elderly.
Magnapen is a combination of two well-proven semi-snythetic penicillins which together offer the theoretical advantages of a broad spectrum of activity, good bioavailability and a low incidence of side-effects. It is of particular value in treating infections in the elderly. In this study the theory is borne out in practice in a population presenting special problems for which this combination seems particularly appropriate. Ninety-six patients have been treated with a course of Magnapen syrup. Of the total entered into the study, 73% of patients were clinically cured following therapy, with a further 19% improved. Clinical failure occurred in 8% of patients. Fifty-two patients were bacteriologically assessable, forty-seven of whom (90%) had infecting organisms cleared by therapy. Side-effects occurred in four patients (4%), one of whom had to discontinue therapy.
D000284:Administration, Oral; D000368:Aged; D000667:Ampicillin / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D001682:Biological Availability; D003023:Cloxacillin / Q000031:analogs & derivatives*; D004338:Drug Combinations; D005260:Female; D005436:Floxacillin / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged
D004338:Drug Combinations; D005436:Floxacillin; D000667:Ampicillin; D003023:Cloxacillin